Drug‐ and non‐drug‐associated QT interval prolongation
Top Cited Papers
Open Access
- 11 June 2010
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (1), 16-23
- https://doi.org/10.1111/j.1365-2125.2010.03660.x
Abstract
Sudden cardiac death is among the most common causes of cardiovascular death in developed countries. The majority of sudden cardiac deaths are caused by acute ventricular arrhythmia following repolarization disturbances. An important risk factor for repolarization disturbances is use of QT prolonging drugs, probably partly explained by gene–drug interactions. In this review, we will summarize QT interval physiology, known risk factors for QT prolongation, including drugs and the contribution of pharmacogenetics. The long QT syndrome can be congenital or acquired. The congenital long QT syndrome is caused by mutations in ion channel subunits or regulatory protein coding genes and is a rare monogenic disorder with a mendelian pattern of inheritance. Apart from that, several common genetic variants that are associated with QT interval duration have been identified. Acquired QT prolongation is more prevalent than the congenital form. Several risk factors have been identified with use of QT prolonging drugs as the most frequent cause. Most drugs that prolong the QT interval act by blocking hERG‐encoded potassium channels, although some drugs mainly modify sodium channels. Both pharmacodynamic as well as pharmacokinetic mechanisms may be responsible for QT prolongation. Pharmacokinetic interactions often involve drugs that are metabolized by cytochrome P450 enzymes. Pharmacodynamic gene–drug interactions are due to genetic variants that potentiate the QT prolonging effect of drugs. QT prolongation, often due to use of QT prolonging drugs, is a major public health issue. Recently, common genetic variants associated with QT prolongation have been identified. Few pharmacogenetic studies have been performed to establish the genetic background of acquired QT prolongation but additional studies in this newly developing field are warranted.Keywords
This publication has 65 references indexed in Scilit:
- Common variants at ten loci influence QT interval duration in the QTGEN StudyNature Genetics, 2009
- Clinically relevant QTc prolongation due to overridden drug–drug interaction alerts: a retrospective cohort studyBritish Journal of Clinical Pharmacology, 2009
- Cellular basis of drug‐induced torsades de pointesBritish Journal of Pharmacology, 2008
- Congenital long QT syndromeOrphanet Journal of Rare Diseases, 2008
- A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarizationNature Genetics, 2006
- Atypical AntipsychoticsDrug Safety, 2005
- Drug-Induced Prolongation of the QT IntervalThe New England Journal of Medicine, 2004
- Pharmacogenetic Aspects of Drug-Induced Torsade de PointesDrug Safety, 2004
- Long QT syndromes and torsade de pointesThe Lancet, 1999
- Influence of the Genotype on the Clinical Course of the Long-QT SyndromeThe New England Journal of Medicine, 1998